JP2023549555A5 - - Google Patents
Info
- Publication number
- JP2023549555A5 JP2023549555A5 JP2023529918A JP2023529918A JP2023549555A5 JP 2023549555 A5 JP2023549555 A5 JP 2023549555A5 JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023529918 A JP2023529918 A JP 2023529918A JP 2023549555 A5 JP2023549555 A5 JP 2023549555A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- sequence
- seq
- isolated antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115272P | 2020-11-18 | 2020-11-18 | |
| US63/115,272 | 2020-11-18 | ||
| US202163244662P | 2021-09-15 | 2021-09-15 | |
| US63/244,662 | 2021-09-15 | ||
| PCT/US2021/059955 WO2022109178A1 (en) | 2020-11-18 | 2021-11-18 | Anti-marco antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549555A JP2023549555A (ja) | 2023-11-27 |
| JP2023549555A5 true JP2023549555A5 (cg-RX-API-DMAC7.html) | 2024-11-20 |
Family
ID=81588283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529918A Pending JP2023549555A (ja) | 2020-11-18 | 2021-11-18 | 抗marco抗体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11572407B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4247419A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023549555A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230121759A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021382658A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198579A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302874A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005841A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237648A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022109178A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237648A (zh) | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
| US20250011410A1 (en) * | 2021-11-23 | 2025-01-09 | Invetx, Inc. | Anti-ngf antibodies and uses thereof |
| US20260008844A1 (en) * | 2022-09-15 | 2026-01-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer |
| US20260126450A1 (en) * | 2022-10-12 | 2026-05-07 | Massachusetts Institute Of Technology | Library-scale methods for polypeptide functional analysis |
| WO2025102054A1 (en) * | 2023-11-09 | 2025-05-15 | Massachusetts Institute Of Technology | Methods of screening for secreted functional molecules |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916766A (en) | 1996-05-23 | 1999-06-29 | Smithkline Beecham Corporation | Human marco scavenger receptor |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US20100227415A1 (en) | 2007-07-24 | 2010-09-09 | Iss Immune System Stimulation Ab | Method and means for prediction of systemic lupus erythematosus susceptibility |
| US8597946B2 (en) | 2008-03-10 | 2013-12-03 | H. Lee Moffitt Caner Center and Research Institute, Inc. | Enhanced dendritic cells for cancer immunotherapy |
| KR20130108295A (ko) * | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| WO2012122396A1 (en) | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| WO2016196612A1 (en) | 2015-06-01 | 2016-12-08 | The Rockefeller University | Anti-tumor agents and methods of use |
| WO2017062363A1 (en) | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Methods of use of betatrophin |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| EP3612563A1 (en) | 2017-04-19 | 2020-02-26 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| TW201904588A (zh) | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| EP3668899A4 (en) | 2017-08-18 | 2020-09-02 | Celdara Medical, LLC | CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES |
| PL3688155T3 (pl) | 2017-09-28 | 2023-09-11 | Immpact-Bio Ltd. | Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) |
| MX2020006654A (es) | 2017-12-22 | 2020-11-06 | Atossa Therapeutics Inc | Métodos intraductales de tratamiento de trastornos de mama. |
| MX387358B (es) | 2018-02-28 | 2025-03-18 | Pfizer | Variantes de il-15 y usos de las mismas |
| BR112021006100A2 (pt) | 2018-09-28 | 2021-07-20 | Immpact-Bio Ltd. | métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer |
| JP2022514215A (ja) * | 2018-12-05 | 2022-02-10 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Rankアンタゴニストおよびその使用 |
| EP3906055A4 (en) | 2019-01-04 | 2023-01-04 | Trio Pharmaceuticals, Inc. | MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES |
| WO2020162696A1 (ko) | 2019-02-08 | 2020-08-13 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
| US20220152148A1 (en) | 2019-03-18 | 2022-05-19 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
| IL287801A (en) | 2019-05-07 | 2022-07-01 | Immunicom Inc | Increasing responses to checkpoint inhibitors by extracorporeal apheresis |
| GB2603044B (en) | 2019-06-11 | 2024-08-21 | Myeloid Therapeutics Inc | Macrophage specific engager compositions and methods of use thereof |
| KR20220054305A (ko) | 2019-07-31 | 2022-05-02 | 온코어 파마, 인크. | 면역 회피성 종양의 치료 |
| TW202237648A (zh) | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
-
2021
- 2021-11-18 TW TW110143070A patent/TW202237648A/zh unknown
- 2021-11-18 EP EP21895613.4A patent/EP4247419A4/en active Pending
- 2021-11-18 IL IL302874A patent/IL302874A/en unknown
- 2021-11-18 CA CA3198579A patent/CA3198579A1/en active Pending
- 2021-11-18 JP JP2023529918A patent/JP2023549555A/ja active Pending
- 2021-11-18 AU AU2021382658A patent/AU2021382658A1/en active Pending
- 2021-11-18 KR KR1020237020512A patent/KR20230121759A/ko active Pending
- 2021-11-18 US US17/529,927 patent/US11572407B2/en active Active
- 2021-11-18 WO PCT/US2021/059955 patent/WO2022109178A1/en not_active Ceased
- 2021-11-18 MX MX2023005841A patent/MX2023005841A/es unknown
-
2022
- 2022-12-19 US US18/068,237 patent/US12378311B2/en active Active
-
2025
- 2025-07-03 US US19/260,221 patent/US20260172900A1/en active Pending